Please login to the form below

Not currently logged in
Email:
Password:

market share

This page shows the latest market share news and features for those working in and with pharma, biotech and healthcare.

Bayer, Orion prep challenge in prostate cancer market

Bayer, Orion prep challenge in prostate cancer market

Darolutamide is facing some entrenched, heavyweight rivals in the market for anti-androgen prostate cancer therapies, which is currently led by Johnson &Johnson with Zytiga (abiraterone acetate) and next-generation drug ... It got a green light in Europe

Latest news

More from news
Approximately 0 fully matching, plus 485 partially matching documents found.

Latest Intelligence

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    Of this total, treatments for lung cancer represented nearly half of the global market share in 2017, and are expected to continue rapid growth in 2019 and beyond. ... its marketing and sales efforts to maximise its market share.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    At the moment Shire’s big competitor in HAE is CSL with its Haegarda product, a subcutaneous medicine that launched last year and has been trying to steal market share from ... In the long term, a US market share of 10% of the number of patients treated

  • Is China ready for a pharmaceutical gold rush?

    In 2016, this share was valued at around $446bn. The Chinese market is second only to that of the United States and is the fastest growing in the world. ... Many of the western pharma companies that have succeeded in this new world to date have done so,

  • Biopharma's Future: Made in China Biopharma's Future: Made in China

    and a series of sweeping reforms is now opening China’s pharma market to rapid modernisation. ... Obstacles remain. There remain some major potential pitfalls for pharma companies competing for a share of this rapidly-expanding market.

  • The race for a HIV ‘cure’ The race for a HIV ‘cure’

    GSK’s majority-owned ViiV Healthcare is the strongest challenger to Gilead’s 52% market share. ... bringing it to market if it is totally uninteresting and of no need to patients,” said Elliott.

More from intelligence
Approximately 1 fully matching, plus 62 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 49 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

2019: CRISPR and therapeutic gene editing comes of age
Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases?...
The 10-year Web Challenge
Understanding your users’ needs is more critical online today than ever. A site should mould itself around these insights, deliver those needs quickly, efficiently and with plenty of white space....
Downloadable Pack: Understanding Multiple Sclerosis
Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry....

Infographics